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Abstract
Background: Autoinflation balloons are used to treat patients with otitis media with effusion (OME) to 
help avoid surgery.
Aim: To compare the ability of party balloons with Otovent balloons to produce sufficient pressure for 
a Valsalva manoeuvre.
Design & setting: Pressure testing was used to determine the number of times each balloon could 
produce pressures sufficient for a Valsalva manoeuvre. Subsequently, Otovent balloons were compared 
with spherical party balloons in a pilot clinical trial of 12 healthy adults.
Method: Each balloon was inflated 20 times and the maximum pressure was recorded. Three balloons 
of each type were tested to 50 inflations to assess pressures over persistent use.
Results: Otovent balloons’ mean inflation pressure was 93 mmHg (95% confidence interval [CI] = 89 
to 97 mmHg) on first inflation, dropping to 83 mmHg (95% CI = 80 to 86 mmHg) after 20 inflations. 
Two types of spherical party balloon required mean inflation pressures of 84 mmHg (95% CI = 77 to 
90 mmHg) and 108 mmHg (95% CI = 97 to 119 mmHg) on first inflation, dropping to 74 mmHg (95% 
CI = 68 to 81 mmHg) and 83 mmHg (95% CI = 77 to 88 mmHg) after 20 inflations. In the pilot trial, 
there was no difference between the ability of Otovent and spherical balloons (χ2 = 0.24, P = 0.89) to 
produce the sensation of a Valsalva manoeuvre.
Conclusion: Otovent balloons can be used more than the 20 times quoted by the manufacturer. 
The two spherical balloons produced similar pressures to Otovent balloons, indicating potentially the 
same clinical effect. The pilot study suggests a potential use of spherical party balloons instead of 
Otovent balloons as a cost- efficient treatment.
How this fits in
Autoinflation balloons, such as Otovent, can be used as an effective treatment option in OME. This 
research shows that two types of spherical party balloons are able to produce similar pressures to Otovent 
balloons. It also shows that both Otovent and spherical party balloons are capable of producing sufficient 
pressure for a Valsalva manoeuvre for at least 50 inflations. This provides the potential for reduced cost 
autoinflation treatment for children with OME.
Introduction
OME, commonly known as glue ear, is a non- inflammatory fluid blockage in the middle ear,1 without 
symptoms of acute infection. Grommet insertion to treat glue ear is the most common reason for a 
surgical procedure in childhood in the UK, with 25 000 procedures performed each year.2 OME has 
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a point prevalence of 20% in 2 year olds,3 and by the age of 4 years has a cumulative incidence of 
80%.4 OME can lead to conductive hearing loss; for patients with bilateral OME for over a month, 
this can be as great as 20–30dB.5 This hearing loss resolves in 95% of cases within a year,6 although 
patients may experience linguistic, developmental, and behavioural consequences.7 Current National 
Institute for Health and Care Excellence (NICE) guidelines suggest a 3- month period of watchful 
waiting8 as OME has been shown to resolve in 50% of cases during this period.9 Furthermore, in 
children aged <3 years, a delay of 6 months in surgical treatment does not appear to significantly 
affect developmental outcomes.10 Medical treatment options include mucolytics, antihistamines, 
corticosteroids, decongestants,11 and antibiotics.12 Antibiotic treatments show either short- lived 
benefit for 1 month13 or no benefit at all.14 Corticosteroids can be effective in the short term,15 
although no long- term benefit has been shown.16
Autoinflation balloons can be used to treat OME, as shown in a recent systematic review,17 with 
a number needed to treat of 9.18 These balloons equalise the pressure between the middle ear 
and nasal cavity. The intranasal pressure is increased on inflation of the balloon, forcing open the 
eustachian tube and equalising the negative pressure. This process is a Valsalva manoeuvre,19 with 40 
mmHg usually quoted for an effective Valsalva manoeuvre (range of 30–50 mmHg).20–24 The balloon 
provides a visual aid to help the patient complete a Valsalva manoeuvre. Otovent balloons are a type 
of autoinflation balloon sold as a set of five with a nosepiece. The balloon is fitted to the flat end of 
the nosepiece while the ball- shaped section is placed to form a tight seal against the nostril; the other 
nostril is compressed.25 Manfacturers of Otovent balloons recommend a maximum of 20 inflations per 
balloon, so Otovent balloons were tested to determine after how many repeated inflations they could 
produce a pressure of 40 mmHg. Four different types of party balloons were also tested to determine 
whether they could reach adequate pressures to be used as a potential alternative method for the 
treatment of OME.
Method
A novel protocol was designed using the Omron PA350e blood pressure monitor tester to inflate the 
balloons and measure the pressure (Figure 1a). The pressure- testing device has previously been used 
to assess the accuracy of sphygmomanometers used in primary care.26 This apparatus consisted of 
three pieces of rubber tubing linked together by connectors, with one end attached to the nosepiece 
designed for Otovent balloons.25 To inflate the balloon, air was pumped through the plastic tubing 
into the balloon allowing the pressure within to be measured.
As the balloon inflated, the pressure within rose until a critical point when the volume of air within 
the balloon continued to increase but the pressure decreased. After the maximum pressure had been 
reached by each balloon (shown by a decline in pressure despite an increase in volume) the machine 
was turned off, allowing the balloon to deflate. This process was repeated 20 times unless the balloon 
Figure 1 Test equipment used in the study. (Figure 1a) Omron PA350e blood pressure monitor used to test the maximum pressure achieved by each 
balloon, connecting tubes, nosepiece, and Otovent balloon. (Figure 1b) Balloons tested, left to right: Otovent (A), modelling (B), spiral (C), sphere 1 (D), 
sphere 2 (E)
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burst, as this is the limit quoted by Otovent. Each inflation was video- recorded, enabling the digital 
display of the machine to be checked to determine the maximum pressure reached by each balloon.
Five different types of balloons were tested (Figure 1b); eight Otovent balloons (A), and 10 party 
balloons of each of four different types (modelling [B], spiral [C], sphere 1 [D], and sphere 2 [E]). The 
party balloons selected were easily available and included a range of shapes, sizes, and manufacturers. 
The modelling balloons were long and thin, while the spiral balloons were long and irregularly shaped. 
The Otovent (A) and sphere 2 (E) balloons were small and spherical; sphere 1 (D) balloons were 
larger in size but had the same shape. All available colours of balloons were tested to give an initial 
indication as to whether colour affected the maximum pressure of the balloon.
The spiral balloons, owing to their irregular shape, required a maximum pressure to be recorded 
after 5 seconds as well as after 30 seconds. This allowed the pressures within the balloon to be 
acurrately determined throughout the course of the 20 inflations. Four of the 10 modelling balloons 
did not inflate despite being pressurised to 300 mmHg (the maximum pressure produced by the 
testing device) and, therefore, were removed from the analysis.
In addition, three of each of the Otovent (A), sphere 1 (D), and sphere 2 (E) balloons were subjected 
to an extended test of 50 inflations to determine if they were still able to achieve the pressure of 40 
mmHg.
The data for each inflation number for each balloon was summarised by mean and CIs. Linear 
regression was then used to analyse the data. These equations were used to extrapolate the data 
until the point at which a Valsalva manoeuvre could no longer occur (maximum pressure of 40 mmHg). 
Following this, a linear mixed- effects model was used with both varying intercept and varying slope, 
allowing for the original grouping of the data by individual balloon. This model allowed variability 
between different balloons of the same type to be determined. Furthermore, this data was used 
to determine the longevity of the ‘worst predictable’ balloon. This was determined by finding the 
mean minus 2SD for the intercept and slope. All CIs are 95%, and results were considered statistically 
significant if the P value was <0.05. Analyses were performed in R (version 3.3.1).
Pilot clinical trial
Following the successful tests of both spherical balloons (D and E), a pilot clinical trial was carried 
out to determine their effectiveness in ability to perform a Valsalva manoeuvre in comparison with 
Otovent balloons (A). Participants were healthy, aged 18–65 years and recruited via word of mouth. 
Exclusion criteria included having history of recent nasal trauma or bruising; severe coronary artery 
disease; a moderate to severe reduction in blood volume; or having experienced a recent heart attack. 
Informed consent was achieved by a verbal explanation of the study at the time of consent as well as 
a participant information sheet; 12 participants gave their written informed consent.
Participants were randomised into three groups and used the balloons in three different orders 
(ADE, DEA, and EAD, respectively). It was not possible to use a placebo or to double- blind the trial 
by masking which balloons were being used. Each participant was asked to inflate the three balloons 
in turn by placing the balloon to one nostril, covering the other, and breathing out into the balloon; 
it was recorded whether they felt their ear 'pop'. Inflation was carried out without a nosepiece for 
Table 1 Mean and 95% confidence intervals of maximum pressures (mmHg) achieved during the first 30 seconds of inflation for each 
balloon type
Balloon type
Initial inflation After 20 inflations After 50 inflations
n Mean (mmHg)
95% confidence interval 
(mmHg)
Mean 
(mmHg) 95% confidence interval 
(mmHg) Mean (mmHg)
95% confidence interval 
(mmHg)
Otovent (A) 8 92.9 88.9 to 96.8 82.7 79.6 to 85.7 77.4 74.0 to 80.8
Modelling (B) 10 278.1 221.14 to 335.0 107.5 75.7 to 139.2 n/a n/a
Spiral – 5 seconds (C) 10 79.77 70.6 to 89.0 58.5 53.6 to 63.4 n/a n/a
Spiral – 30 seconds (C) 10 74.77 64.6 to 84.8 62.1 57.5 to 66.7 n/a n/a
Sphere 1 (D) 10 83.6 77.3 to 90.0 74.0 67.5 to 80.5 71.2 66.5 to 75.9
Sphere 2 (E) 10 107.7 96.5 to 118.9 82.6 77.3 to 87.9 77.1 67.8 to 86.4
Marshall K et al. BJGP Open 2021; DOI: 10.3399/BJGPO.2020.0178
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all balloons. If this occurred, a Valsalva manoeuvre was deemed to have successfully taken place. 
A successful Valsalva manoeuvre was recorded as either a ‘yes’ or ‘no’ to ear popping. The results 
were analysed by finding the percentage success rate and followed by a χ2 test of independence to 
compare the groups.
Results
Table 1 shows the mean inflation pressures and CIs for all balloons at initial inflation; after 20 inflations 
(Figure 2, supplementary Figures S2 and S3); and, where relevant, after 50 inflations (Figure S1). The 
modelling balloons (B) were found to require excessively high inflation pressures. The long spiral 
balloons (C) had an unpredictable and variable pressure response during inflation, with two balloons 
bursting, making their results unreliable. The Otovent balloons (A) achieved the required pressure 
throughout testing, along with both types of spherical party balloon (D and E). All of these balloons 
showed linear decreases in the pressure required to inflate them from the second inflations.
Linear regression analysis
Sphere 1 (D) had the shallowest gradient closely followed by Otovent (A) and then sphere 2 (E). 
Sphere 2 (E) had the highest intercept, before Otovent (A) and then sphere 1 (D) (supplementary 
Figure S4). The results were extrapolated to predict how many times the balloons could be inflated 
before they were no longer able to carry out a Valsalva manoeuvre (Table 2).
Table 2 Linear regression results (inflation number 2–50) for Otovent (A), sphere 1 (D), and sphere 2 (E)
Balloon n Equation CI intercept CI gradient P value of gradient
Predicted number of inflations
when maximum pressure is 40 mmHg















Figure 2 Mean inflation pressures (2–20) and standard deviation of (Figure 2a) Otovent (A), n = 8; (Figure 2b) sphere 1 (D), n = 10; (Figure 2c) sphere 2 
(E), n = 10.
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Mixed-effect model
To analyse the variability between different balloons of the same type, a mixed- effect model was 
used. Sphere 2 (E) had the highest intercept followed by Otovent balloons (A) and sphere 1 (D), 
as shown in Table 3. Sphere 1 (D) had the shallowest gradient, followed by Otovent (A) and then 
sphere 2 (E). When comparing the ‘worst predictable balloon’ model, Otovent (A) balloons showed 
the least variability and had the highest number of inflations before being unable to complete a 
Valsalva manoeuvre (maximum pressure dropped below 40 mmHg). Sphere 1 (D) balloons lasted for 
more inflations than sphere 2 (E) balloons, but both had a lower maximum inflation number than the 
Otovent (A) balloon. A ‘worst predictable balloon’ model was calculated using mean- 2SD for both the 
intercept and slope.
Pilot clinical study results
Participants had an equal success rate with Otovent balloons (A) and sphere 2 (E) balloons (Table 4). 
The χ2 test showed no difference between the three balloon groups (χ2 = 0.2408, P = 0.887).
Discussion
Summary
Overall, it has been shown that Otovent balloons can be used more than the 20 times printed on the 
manufacturer’s guidelines, and will still be able to produce a Valsalva manoeuvre after at least 50 uses. 
Furthermore, it has been shown that spherical party balloons are able to produce similar pressures for a 
similar number of inflations. Balloon shape is an important factor in the use of party balloons, as neither 
the modelling nor spiral balloons were effective owing to the long and either irregular or thin shape. 
As the current NICE guidelines8 suggest a period of watchful waiting for the first 3 months before any 
surgical treatment, the use of spherical party balloons could provide a cost- efficient treatment option 
during this time period. Extrapolating the linear regression and mixed- model data suggests that it 
would take over nine times the manufacturer’s limit of 20 inflations before Otovent balloons were no 
longer able to reach the necessary pressure. However, party balloons (sphere 1 [D] and sphere 2 [E]) 
are still able to be inflated at least four times and three times respectively more than the Otovent 
manufacturer's limit (even when looking at the ‘worst predictable balloon’ extrapolation), showing 
their possible effectiveness in clinical practice. Autoinflation balloons were able to be tested against 
spherical balloons for the first time in healthy patients allowing their effectiveness at performing a 
Valsalva manoeuvre and their subsequent 
potential use in the treatment of OME.
Strengths and limitations
A range of party balloons were able to be 
tested from a variety of different manufacturers. 
Guidance for the use of Otovent balloons 
suggests that an adult inflates the balloon for 
the first time to show the child how to use it and 
to overcome the larger pressure required for 
the first inflation. This further supports the use 
of sphere party balloons as the larger pressure 
Table 3 Mixed- effect model for inflation numbers 2–50: results and inflation number of 'worst pre-
dictable' balloon for Otovent (A), sphere 1 (D), and sphere 2 (E).
Balloons
Intercept Slopes ‘Worst predictable balloon’
inflation number when maximum 
pressure is 40 mmHgn Mean SD Mean SD
Otovent (A) 8 86.75 1.446 –0.204 0.0163 185
Sphere 1 (D) 10 77.50 3.384 –0.18 0.0866 87
Sphere 2 (E) 10 90.20 2.377 –0.402 0.156 63
Table 4 Success rates of Otovent (A), sphere 1 
(D), and sphere 2 (E) in causing a Valsalva ma-









Otovent (A) 12 66.7 40.0 to 93.3
Sphere 1 (D) 12 58.3 30.4 to 86.2
Sphere 2 (E) 12 66.7 40.0 to 93.3
Marshall K et al. BJGP Open 2021; DOI: 10.3399/BJGPO.2020.0178
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required to initially inflate sphere 2 (E) balloons (Table 3) could be negated by adult assistance. All 
balloons were tested under repeated stress that was greater than would have been experienced by 
normal use. Inflations for each balloon happened in quick succession compared with three inflations 
per day in ordinary use of Otovent balloons. This was demonstrated by a pressure increase between 
inflations 20 and 21 (supplementary Figure S1), as two of the three balloon types did not have the 
final 30 inflations carried out immediately after the first 20. This might suggest that the balloons 
could still achieve the required pressures for even more inflations if the intervals between inflations 
were longer.
The analysis considers the variability between different balloons tested, although, as the values 
are extrapolated, an individual balloon may burst before this point. The main limitation was the use 
of the nosepiece to attach all balloons to the tubing connected to the pressure monitor. If spherical 
party balloons in treatment were used as opposed to Otovent, then the nosepiece would not be 
available; this could prevent a seal being created to inflate the balloons. However, in the pilot clinical 
trial, participants still reported a Valsalva manoeuvre despite the absence of a nosepiece. It was not 
possible to blind the participants as to which balloon they were using, although this reflected how 
these balloons would be used in routine practice. The sample size of the pilot clinical trial was limited 
by the number of Otovent balloons remaining from the original data collection and, consequently, so 
was the power of the analysis. Therefore, it would only have been possible to detect large differences 
between the three groups.
The experiment did not assess the effect of different inflation speeds, or of different volumes 
required to attain a pressure sufficient to achieve a Valsalva manoeuvre. The equipment used inflates 
at a roughly constant speed, which is probably faster than that which could be achieved by a person, 
particularly a child.
Comparison with existing literature
In comparison with a previous study with party balloons,27 the ability of specialised autoinflation 
balloons was compared with party balloons. Also, unlike previous experiments, the maximum pressure 
reached by each balloon via a pressure monitor was determined in order to assess whether a Valsalva 
manoeuvre could take place. Recent randomised clinical trials28 suggest that autoinflation is an 
effective way for treating OME during the watchful- waiting period and this study's results confirm the 
reliability of Otovent balloons to consistently reach the required pressure for a Valsalva manoeuvre.
Implications for research and practice
The results have suggested that spherical party balloons and Otovent balloons have limited differences 
for patients owing to the ‘all- or- nothing’ nature of a Valsalva manoeuvre. This implies that spherical 
party balloons could be used instead of Otovent balloons for treatment of OME, which would provide 
large cost savings. Otovent balloons are sold in a pack of five and, at drug tariff prices, are £0.98 per 
balloon, while the spherical balloons used in this study are sold in packs of 50 and average £0.029 
per balloon. The recommended treatment time for autoinflation balloons is between 1 and 3 months 
(during the NICE guideline recommended watchful- waiting period). Therefore, if a balloon has a 
maximum of 20 inflations (based on Otovent instructions) and is to be used three times per day, five 
balloons would be required per month of treatment. For 1 month, the cost would be £0.15 (spherical) 
compared with £4.90 (Otovent), while for 3 months of treatment this would be £0.45 (spherical) 
compared with £14.70 (Otovent). Further savings could be obtained if a larger number of inflations 
were used before discarding a balloon, which the data indicates may be possible.
Further experiments need to be carried out in a randomised control trial to compare the use of 
spherical party balloons with specialised Otovent balloons on a paediatric patient group with OME, to 
test compliance as well as effectiveness. Otovent balloons have been shown to have a compliance rate 
of 80% at 3 months.18 It would also be important to test whether or not a nosepiece is necessary to 
create the seal required to reach the necessary pressure to perform a Valsalva manoeuvre, especially 
in a young child under supervision. An alternative could be to use a nosepiece initially and then 
transition to using party balloons with or without the original nosepiece. Further research is also 
needed to test whether there is an infection risk of repeatedly using any balloon type beyond the 20 
inflation Otovent manufacturer’s limit.
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